Stockscreener 앱 받기
84.45
1.04%
-0.89
Novo Nordisk Adr 주식(NVO)의 최신 뉴스
Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades. - The Motley Fool
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial - Morningstar
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs - Morningstar
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Is Now The Time To Buy PDD Holdings Inc ADR (NASDAQ: PDD) Stock? - Stocks Register
Where Do Analysts Think The Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Is Going - Stocks Register
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Precidian Investments Builds Out Its ADRhedged ETF Lineup with Four New Strategies, Offering Targeted International Exposure with Integrated Currency Hedge - Business Wire
Eli Lilly, Novo Nordisk Went Head-to-Head on Weight-Loss Drugs in 2024. There’s a Clear Winner. - Barron's
Is Alibaba Group Holding Ltd ADR’s (NYSE:BABA) Stock On The Decline? - Stocks Register
European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading - MSN
Will Novo Nordisk (NVO) Stock Recover To $145 Levels? - Forbes
Weekly Upgrades and Downgrades - InvestorPlace
NVO Stock Plunges As Obesity Drug CagriSema Misses Target In Phase III - Barchart
Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. - Barron's
Markets News, December 20, 2024: Stocks Rise After Encouraging Inflation Data to Wrap Up Rough Week; Major Indexes Post Weekly Losses - Investopedia
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment - Morningstar
European Equities Traded in the US as American Depositary Fall in Wednesday Trading - MSN
Novo Nordisk A/S - GlobeNewswire Inc.
0.47%
4.70%
자본화:
|
볼륨(24시간):